Main Arena II, Tuesday, Oct. 31, First Report Investigations 2

Slides:



Advertisements
Similar presentations
Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.
Advertisements

A multicenter, randomized, prospective DKCRUSH-III study
CREATE Multi-Center Clinical Registry 9-month Angiographic and 12-month Clinical Results Yaling Han MD, FSCAI On behalf of the CREATE investigators ACC.
Comparison of the New Mayo Clinic Risk Scores and Clinical SYNTAX Score in Predicting Adverse Cardiovascular Outcomes following Percutaneous Coronary Intervention.
PROSPECTIVE OBSERVATIONAL MULTICENTER STUDY ON THE MANAGEMENT OF INTERMEDIATE CORONARY STENOSES: The Functional or morphological Lesion Assessment for.
FRACTIONAL FLOW RESERVE versus ANGIOGRAPHY
To stent or not to stent Clinical Utility of Fractional Flow Reserve.
Multivessel coronary disease diagnosed at the time of primary PCI for STEMI: complete revascularization versus conservative strategy. PRAGUE 13 trial O.
Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial Jiang He, Yonghong Zhang, Tan Xu, Weijun Tong, Shaoyan Zhang,
Anterior Depressions Angiographic and Clinical Outcomes Among Patients with Acute Coronary Syndromes Presenting with Anterior ST-Segment Depressions C.
Seung-Jung Park, MD, PhD On behalf of the PRECOMBAT Investigators Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan.
CORONARY PRESSURE MEASURENT AND FRACTIONAL FLOW RESERVE
DEFER STUDY: 5-YEAR FOLLOW-UP A Multicenter Randomized Study
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Multiple risk factors raise ischaemic stroke risk comparable to AF in the elderly: A large Chinese insurance analysis from 425,600 Chinese individuals.
Multi-vessel disease and intracoronay physiology Combat MI 2009 Kees-joost Botman MD, PhD Catharina hospital Eindhoven Heart Institute The Netherlands.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
A Randomized Comparison of Everolimus-­ Eluting Absorb Bioresorbable Vascular Scaffolds vs. Everolimus-Eluting Metallic Stents: One-Year Angiographic and.
Determination of the RAdial versus GrOiN coronary angioplasty The Result of DRAGON Trial Shigeru Saito, MD Department of Cardiology and Catheterization.
Two-Year Outcomes After Everolimus- or Sirolimus- Eluting Stents in Patients With Coronary Artery Disease in the ISAR-TEST 4 Trial Robert A. Byrne, Adnan.
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
Robert A. Byrne, MB MRCPI Deutsches Herzzentrum and 1. Med. Klinik rechts der Isar, Technische Universität Munich, Germany A Polymer-Free Dual Drug-Eluting.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
Insights from the PROMISE Trial Neha J. Pagidipati, MD MPH; Kshipra Hemal; Adrian Coles, PhD; Daniel B. Mark, MD MPH; Rowena J. Dolor, MD MHS; Patricia.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Fractional Flow Reserve Calculation From 3-Dimensional.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
Philippe Généreux, MD for the Tryton Bifurcation Trial Investigators Columbia University Medical Center Cardiovascular Research Foundation New York City.
J Am Coll Cardiol 2008;52:636–43 Comprehensive Assessment of Coronary Artery Stenoses Computed Tomography Coronary Angiography Versus Conventional Coronary.
Durable Polymer DES: 5 Year Outcomes RESOLUTE Update Sigmund Silber, MD FESC, FACC, FAHA Heart Center at the Isar Munich, Germany On Behalf of the RESOLUTE.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
Intravascular ultrasound (IVUS) in percutaneous coronary intervention – summary of key articles While angiography is routinely used for assessment of CAD,
Intravascular ultrasound (IVUS) in the treatment of long and diffuse lesions– summary of key articles Prepared by Radcliffe Cardiology 21 November2016.
Total Occlusion Study of Canada (TOSCA-2) Trial
Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Stephen G. Ellis, MD,
Disclosures Runlin Gao has received a research grant
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
Runlin Gao, M.D. On behalf of ABSORB China Investigators
Nico H.J. Pijls, William F. Fearon, Peter Jüni, and Bernard De Bruyne
Updates From NOTION: The First All-Comer TAVR Trial
Quantitative Flow Ratio (QFR)
Damian Gimpel Waikato Cardiothoracic Unit Journal Club
Main Arena IV - Plenary Session XXVII: First Reports #4
Solved & Unsolved Issues
Emerging FFR Non-Wire-based Technology
ADenosine Vasodilator Independent Stenosis Evaluation II
David J. Cohen, M.D., M.Sc. Director of Cardiovascular Research
9:00 AM-9:05 AM, Tuesday, Oct. 31; Room 201/203
The Tryton Bifurcation Trial:
When IVUS? When FFR? Assessing Intermediate Lesions
FAVOR II Europe-Japan FAVOR II E-J
OCT-Guided PCI What needs to be done to establish criteria?
Fractional Flow Reserve Workshop
Circ Cardiovasc Interv
Early strut coverage in patients receiving new-generation drug-eluting stents and its implications for dual antiplatelet therapy: a randomized clinical.
Giuseppe Biondi Zoccai, MD
Kyoto University Hospital, Japan
3-Year Clinical Outcomes From the RESOLUTE US Study
FFRangio Accuracy vs. STandard FFR: Results from the FAST-FFR Trial
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
FOR DISTRIBUTION BY MEDTRONIC OFFICE OF MEDICAL AFFAIRS ONLY.
12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs. metallic drug-eluting.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Presented at TCT 2006.
Impact of Diabetes Mellitus on Long-term Outcomes in the
Patient Examples of CMR Stress Test in Women Patient #1 is a 70-year-old, post-menopausal woman with typical angina and 3 coronary artery disease (CAD)
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Atlantic Cardiovascular Patient Outcomes Research Team
Presentation transcript:

Main Arena II, Tuesday, Oct. 31, First Report Investigations 2 FAVOR II China Diagnostic Accuracy of the Angiographic Quantitative Flow Ratio in Patients With Coronary Artery Disease Bo Xu, MBBS On behalf of the FAVOR II China Investigators 12:45 PM-12:53 PM; Bellco Theater, Meeting Room Level

Disclosure Statement of Financial Interest Funding for the study was provided by the Pulse medical imaging technology (Shanghai) Co., Ltd; the National Key Research and Development Program of China (Grant No. 2016YFC0100500); and the Natural Science Foundation of China (Grant No. 31500797 and 81570456) I, (Bo Xu) have no relevant conflicts of interest to disclose

Background Patients at high risk of having coronary stenosis are evaluated routinely by invasive coronary angiography Fractional flow reserve (FFR) is an increasingly often used method for lesion functional evaluation Studies demonstrated that routine use of FFR allowed reclassification of individual management in a large proportion of patients However, the need for interrogating the stenosis with a pressure wire, the cost of the wire, and the limitations associated with induction of hyperemia have restricted its widespread adoption Curzen N et al. Circ Cardiovasc Interv. 2014;7:248-55; Van Belle E et al. Circulation. 2014;129:173-85; Park SJ et al. Eur Heart J. 2013;34:3353-61

Quantitative Flow Ratio (QFR) Standard Angiogram Data Transmission System Two image runs with angle difference ≥25° AngioPlus System 3D Reconstruction Modified Frame Count QFR QFR = 0.87 + Without Inducing Hyperemia Tu S et al. JACC Cardiovasc Interv. 2014;7:768-77; Tu S et al. JACC Cardiovasc Interv. 2016;9:2024-35

QFR Validation: FAVOR Pilot Study   fQFR ≤ 0.8 cQFR ≤ 0.8 aQFR ≤ 0.8 DS% ≥ 50% Accuracy 80 (71-89) 86 (78-93) 87 (80-94) 65 (55-76) Sensitivity 67 (46-84) 74 (54-89) 78 (58-91) 44 (26-65) Specificity 86 (74-94) 91 (81-97) 79 (66-89) PPV 69 (48-86) 80 (59-93) 81 (61-93) 50 (29-71) NPV 85 (73-93) 88 (77-95) 90 (79-96) 75 (62-85) LR+ 4.8 (2.4-9.5) 8.4 (3.6-20.1) 8.9 (3.7-21.0) 2.1(1.1-4.1) LR- 0.4 (0.2-0.7) 0.3 (0.1-0.5) 0.2 (0.1-0.5) 0.7 (0.5-1.0) AUC 0.88 (0.79-0.94) 0.92 (0.85-0.97) 0.91 (0.83-0.96) 0.72 (0.62-0.82) Good diagnostic accuracy for contrast-flow QFR (without inducing hyperemia); However, QFR analysis was performed in the core lab; QFR accuracy when performed online in the cath lab had not been properly examined to date. Tu S et al. JACC Cardiovasc Interv. 2016;9:2024-35

Objectives To evaluate the diagnostic accuracy of online angiography-based QFR in identifying hemodynamically-significant coronary stenosis by using pressure wire- based FFR as the reference standard

ClinicalTrials.gov NCT0319170 FAVOR II China (N=308) Prospective, multicenter clinical study (in a blinded fashion) Age ≥ 18 years; stable, unstable angina; diameter stenosis between 30% and 90% in a vessel ≥ 2 mm by visual estimation Myocardial infarction within 72 hours; severe heart failure (NYHA ≥ III); ostial lesions, or main vessels with stenotic side branches downstream the interrogated lesion Major Inclusion: Major Exclusion: Online QFR and QCA assessment (blinded to the investigators who measured FFR) Wire-based FFR measurement Primary Endpoint: Diagnostic accuracy* of online QFR as compared with FFR. Major Secondary Endpoint: Sensitivity^ and specificity‖ of online QFR as compared with online QCA, when using FFR as a reference standard. *Diagnostic accuracy: defined as consistency ratio of QFR evaluated outcomes (≤0.8 or >0.8) with the reference standard FFR evaluated outcomes (≤0.8 or >0.8); ^Sensitivity: proportion of QFR≤0.8 or QCA≥50% in vessels with hemodynamically-significant stenosis as measured by FFR (FFR≤0.8); ‖Specificity: proportion of QFR>0.8 or QCA<50% in vessels without hemodynamically-significant stenosis as measured by FFR (FFR≤0.8). ClinicalTrials.gov NCT0319170

Statistical Assumptions The study was powered for testing both primary and major secondary endpoint For the primary endpoint: Target value = 75% Estimated accuracy = 83% Two-sided type I error = 0.05 277 patients with paired QFR and FFR would yield at least 90% power to achieve target goal Assuming anticipated loss to analysis of 10% due to failed QCA, QFR or FFR assessment, enrollment of 308 patients were required For the major secondary endpoint: Assuming sensitivity and specificity was 0.74 and 0.91 for QFR, while 0.48 and 0.76 for QCA 308 patients would yield >80% power to demonstrate superiority of QFR over QCA

Study Organization Principal Investigator Shengshou Hu, MD Co-Principal Investigator Bo Xu, MBBS and Shubin Qiao, MD Data Management and Data Monitoring CCRF, Beijing, China Angiographic Core Lab Statistical Analysis Medical Research and Biometrics Center, National Center for Cardiovascular Diseases, Beijing, China Sponsor Pulse Medical Imaging Technology (Shanghai) Co., Ltd

Sites and Investigators Hospital, City Patients Enrolled Shengshou Hu, Shubin Qiao, and Bo Xu Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China 140 Xinkai Qu and Weiyi Fang Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China 53 Yundai Chen and Feng Tian Chinese PLA General Hospital, Beijing, China 50 Junqing Yang and Jiyan Chen Guangdong General Hospital, Guangzhou, China 45 Lijun Guo Peking University Third Hospital, Beijing, China 20

Study Flow Chart Between June 13, 2017 and July 20, 2017, 335 patients were assessed for eligibility Enrolled 308 patients, 332 vessels Online QFR and QCA assessment 306 patients, 329 vessels (blinded to the investigators who measured FFR) Routine treatment (left to the discretion of physicians) Offline QFR and QCA assessment, FFR reading by an independent core laboratory (QFR: 306 patients, 330 vessels; QCA: 308 patients, 332 vessel; FFR: 306 patients, 330 vessels Wire-based FFR measurement 306 patients, 330 vessels 27 patients excluded : Withdraw informed consent (n=4) Atrial fibrillation (n=1) Total occlusion (n=1) DS % <30% or >90% (n=9) Ineligible for FFR examination (n=12) Online QFR not available (3 vessels): Angiographic image quality not accepted (n=1) Incomplete data (n=2) Online QCA not available (3 vessels): Incomplete data (n=3) FFR not available (2 vessels): Technical issues (n=1) Slow heart rate (n=1)

Baseline Patient Demographics Patients (N=308) Age, years 61.3 ± 10.4 Women 26.3% Diabetes Mellitus 27.9% Hypertension 60.1% Hyperlipidemia 45.1% Current Smoker 28.2% Family History of CAD 16.6% Previous MI 15.6% Previous PCI 21.1% AMI within 1 Month 4.5% Stable Angina 23.4% Unstable Angina 61.0% Left Ventricular Ejection Fraction, % 63.4 ± 6.3

Vessel Characteristics Patients (N=308) Vessels (N=332) Interrogated Vessels Left Anterior Descending Artery 55.7% Diagonal Branch 0.6% Left Circumflex Artery 14.8% Obtuse Marginal Branch 1.5% Ramus Intermediate 0.3% Right Coronary Artery 26.2% Posterior Descending Artery Posterolateral Branch Reference Vessel Diameter, mm 2.82 ± 0.56 Minimal Lumen Diameter, mm 1.51 ± 0.44 Diameter Stenosis, % 46.5 ± 11.3 Lesion Length, mm 13.1 ± 6.4

Lesion/Procedural Characteristics Patients (N=308) Vessels (N=332) Bifurcation Lesions 24.7% Tortuous Vessels 14.2% Moderate or Severe Calcified Lesions 18.4% Thrombotic Lesions 0.3% Tandem Lesions 46.3% Online FFR Analysis FFR (Per Vessel) 0.82 ± 0.12 Vessels with FFR ≤ 0.80 34.2% Vessels with 0.75 ≤ FFR ≤ 0.85 32.4% Patients with FFR Measurement in > 1 Vessel 7.2% Mean Time for QFR Assessment, mins 4.36 ± 2.55

Correlation and Agreement of QFR and FFR (Online Analysis) r = 0.857, p < 0.001 Mean difference: -0.01, SD: 0.063, p = 0.006 0.4 0.6 0.8 1.0 -0.2 0.0 0.1 0.2 -0.1 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Mean + 1.96 SD Mean Mean - 1.96 SD QFR - FFR QFR FFR (QFR + FFR) / 2

Primary Endpoint: Online Per-Vessel QFR Diagnostic Accuracy Point Estimate: 92.7% (304/328) 95% Confidence Interval: 89.3% to 95.3% Target Value 75% p Value < 0.0001 Prespecified Target Value = 75% Accuracy = 92.7% % 55 60 65 75 80 85 50 70 95 90 Two-sided 95% CI Prespecified Performance Goal Met

Diagnostic Accuracy of QFR in Different Interrogated Vessels Estimate, % (95% CI) No. of Patients in Group LAD 92.4 (87.6, 95.8) 184 LCX 96.4 (87.5, 99.6) 55 RCA 91.0 (83.1, 96.0) 89 Difference, % (95% CI) p Value LAD vs. LCX -4.0 (-9.9, 2.3) 0.30 LAD vs. RCA 1.4 (-5.5, 8.8) 0.70 LCX vs. RCA 5.4 (-2.3, 13.7) 0.22

Difference Between QFR and FFR Diagnostic Consistency for Identifying Hemodynamically-Significant Stenosis by QFR and FFR FFR > 0.8 FFR ≤ 0.8 QFR > 0.8 198 6 QFR ≤ 0.8 18 106 Difference Between QFR and FFR > 0.05 31.4% (103/328) > 0.1 8.5% (28/328) LAD 10.3% (19/184) LCX 5.5% (3/55) RCA 6.7% (6/89)

Online Per-Patient Diagnostic Accuracy of QFR Point Estimate: 92.4% (281/304) 95% Confidence Interval: 88.9% to 95.1% Target Value 75% p Value < 0.0001 Prespecified Target Value = 75% Accuracy = 92.4% % 55 60 65 75 80 85 50 70 95 90 Two-sided 95% CI Prespecified Performance Goal Met

Diagnostic Performance of QFR and QCA Diameter Stenosis by QCA ≥ 50% (Online Analysis) QFR ≤ 0.8 Diameter Stenosis by QCA ≥ 50% Difference 95% (CI) p Value Accuracy, % 92.7 (89.3, 95.3) 59.6 (54.1, 65.0) 34.9 (28.3, 41.5) < 0.001 Sensitivity, % 94.6 (88.7, 98.0) 62.5 (52.9, 71.5) 32.0 (21.0, 43.1) Specificity, % 91.7 (87.1, 95.0) 58.1 (51.2, 64.8) 36.1 (27.9, 44.3) PPV, % 85.5 (78.0, 91.2) 43.8 (35.9, 51.8) 42.0 (31.4, 52.7) NPV, % 97.1 (93.7, 98.9) 74.9 (67.6, 81.2) 24.4 (15.6, 33.2) + LR 11.4 (7.1, 17.0) 1.49 (1.21, 1.85) - - LR 0.06 (0.03, 0.13) 0.65 (0.50, 0.84) PPV = positive predictive value; NPV = negative predictive value; +LR = positive likelihood ratio; -LR = negative likelihood ratio

Diagnostic Performance of QFR and QCA Diameter Stenosis by QCA ≥ 50% (Offline Analysis) QFR ≤ 0.8 Diameter Stenosis by QCA ≥ 50% Difference 95% (CI) p Value Accuracy, % 93.3 (90.0, 95.7) 64.0 (58.6, 69.2) 29.9 (23.2, 36.7) <0.001 Sensitivity, % 94.1 (88.3, 97.6) 49.6 (41.1, 59.7) 44.4 (33.0, 55.7) Specificity, % 92.8 (88.4, 95.9) 72.2 (65.7, 78.2) 21.3 (13.2, 29.4) PPV, % 88.2 (81.3, 93.2) 50.4 (41.0, 59.8) 37.0 (25.4, 48.6) NPV, % 96.5 (93.0, 98.6) 71.6 (65.0, 77.5) 26.8 (18.5, 35.0) + LR 13.1 (8.04, 21.0) 1.81 (1.36, 2.40) - - LR 0.06 (0.03, 0.13) 0.69 (0.57, 0.84) PPV = positive predictive value; NPV = negative predictive value; +LR = positive likelihood ratio; -LR = negative likelihood ratio

Difference 0.31 [95% CI: 0.24, 0.37], p < 0.0001 Receiver Operating Curves for the Discrimination of Functionally Significant Stenosis (Online Analysis) Sensitivity QFR: AUC 0.96 [95% CI: 0.94, 0.98] QCA: AUC 0.66 [95% CI: 0.59, 0.72] Difference 0.31 [95% CI: 0.24, 0.37], p < 0.0001 1-Specificity

Diagnostic Performance of QFR and QCA in Subgroup of DS% [40% - 80%] by Visual Estimation QFR ≤ 0.8 Diameter Stenosis by QCA ≥ 50% Difference 95% (CI) p Value Accuracy, % 92.3 (88.5, 95.2) 58.5 (52.4, 64.4) 36.6 (29.2, 44.1) < 0.001 Sensitivity, % 92.2 (83.8, 97.1) 54.5 (42.8, 65.9) 44.1 (28.4, 59.9) Specificity, % 92.3 (87.7, 95.7) 60.0 (52.8, 66.9) 35.1 (26.4, 43.8) PPV, % 82.6 (72.9, 89.9) 35.0 (26.5, 44.2) 50.5 (37.0, 64.1) NPV, % 96.8 (93.1, 98.8) 77.0 (69.5, 83.4) 22.9 (13.8, 32.0) + LR 12.0 (7.34, 20.0) 1.36 (1.04, 1.78) - - LR 0.08 (0.04, 0.18) 0.76 (0.58, 0.99) PPV = positive predictive value; NPV = negative predictive value; +LR = positive likelihood ratio; -LR = negative likelihood ratio

Diagnostic Accuracy of QFR in the FFR “Grey Zone” Subgroup FFR < 0.75 or FFR > 0.85 Estimate, % (95% CI) No. of Vessels in Group QFR Accuracy, % 86.0 (77.9, 91.9) 107 95.9 (92.4, 98.1) 221 For the subgroup with FFR between 0.75 and 0.85 where a small numerical difference between QFR and FFR can lead to clinical discordance, QFR still had high diagnostic accuracy (86.0% [95% CI: 77.9% to 91.9%])

Limitations Not all the vessels were interrogated for the enrolled patients: the vessels with diameter stenosis below 30% or above 90% were not assessed as performing physiological assessment in such lesions was left unnecessary. Side branches of bifurcation lesions with medina type 1,1,1 or 1,0,1 were not assessed. Generalizability of QFR to the side branches of coronary bifurcation lesions still requires further investigation. Although the accuracy of QFR was high in the present study, there was still numerical difference between QFR and FFR. Nevertheless, for the subgroup with FFR between 0.75 and 0.85 where a small numerical difference between QFR and FFR can lead to clinical discordance, QFR still had high diagnostic accuracy. Additionally, there were 15.6% patients with previous myocardial infarction, which might have increased the possibility of inaccurate physiology measurements but also reflects a standard clinical population. As clinical decisions in the study population were based on FFR measurements, it was not possible to directly evaluate clinical outcome by a QFR based diagnostic strategy. Randomized trials comparing clinical outcomes after QFR based diagnostic strategies and standard diagnostic strategies are warranted.

Conclusions The FAVOR II China study met its prespecified primary performance goal for the level of diagnostic accuracy of QFR in identifying hemodynamically-significant coronary stenosis. It demonstrates clinical utility of QFR for use in diagnostic catheterization laboratories and QFR bears the potential of improving angiography- based identification of functionally-significant stenosis during coronary angiography.